188 related articles for article (PubMed ID: 38036153)
1. Toxic warhead-armed antibody for targeted treatment of glioblastoma.
Xi J; Liu K; Peng Z; Dai X; Wang Y; Cai C; Yang D; Yan C; Li X
Crit Rev Oncol Hematol; 2024 Jan; 193():104205. PubMed ID: 38036153
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
3. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
[TBL] [Abstract][Full Text] [Related]
4. Antibody drug conjugates for glioblastoma: current progress towards clinical use.
Gan HK; Parakh S; Osellame LD; Cher L; Uccellini A; Hafeez U; Menon S; Scott AM
Expert Opin Biol Ther; 2023; 23(11):1089-1102. PubMed ID: 37955063
[TBL] [Abstract][Full Text] [Related]
5. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
7. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Mair MJ; Bartsch R; Le Rhun E; Berghoff AS; Brastianos PK; Cortes J; Gan HK; Lin NU; Lassman AB; Wen PY; Weller M; van den Bent M; Preusser M
Nat Rev Clin Oncol; 2023 Jun; 20(6):372-389. PubMed ID: 37085569
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates come of age in oncology.
Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
10. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug Conjugate Targets, Drugs, and Linkers.
Teicher BA; Morris J
Curr Cancer Drug Targets; 2022; 22(6):463-529. PubMed ID: 35209819
[TBL] [Abstract][Full Text] [Related]
15. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440
[TBL] [Abstract][Full Text] [Related]
16. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
17. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
Parakh S; Nicolazzo J; Scott AM; Gan HK
Front Oncol; 2021; 11():718590. PubMed ID: 34926242
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates: Current status and future perspectives.
Gébleux R; Casi G
Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
20. Drug-conjugated antibodies for the treatment of cancer.
Lambert JM
Br J Clin Pharmacol; 2013 Aug; 76(2):248-62. PubMed ID: 23173552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]